It was a pleasure to catch up with our Editorial Board member, Prof. Anat Loewenstein (Tel Aviv Medical Center, Israel), who talked to us about the importance of home monitoring in wet age-related macular degeneration.
- How has the COVID-19 pandemic affected the management of patients with wet age-related macular degeneration (AMD)? (0:10)
- How can home monitoring of visual changes improve the monitoring of wet AMD? (02:36)
- Could you tell us a little about home optical coherence tomography (OCT) technology and its ease of use in elderly populations? (03:36)
- Could you give us an overview of the study of home OCT that you are leading? (04:37)
- What other promising remote monitoring systems are emerging? (05:40)
Speaker Disclosure: Prof. Anat Loewenstein discloses the following: consultant for: Allergan, Bayer, Novartis, Notal – vision, Syneos health, beyeonics surgical, Roche, Pres-By, Xbran, WebMD, KHB, Oxurion.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of EURETINA 2020.
Share this Video
Related Videos In Macular Degeneration
Jordana Fein, ARVO 2023: Phase II CANDELA study post hoc analysis: intravitreal aflibercept injection 8 mg versus 2 mg
The CANDELA trial (NCT04126317) was a phase II, randomized, single-masked, open-label, clinical trial that assessed the safety and efficacy of aflibercept 8 mg versus the standard dose of 2 mg in patients with neovascular age-related macular degeneration (nAMD). It was a pleasure to speak with Dr Jordana Fein (Retina Group of Washington Fairfax, VA, USA) […]
Jordana Fein, ARVO 2023: Current therapeutic options for neovascular age-related macular degeneration
Neovascular age-related macular degeneration (nAMD) is an advanced form of macular degeneration that historically has accounted for the majority of vision loss related to AMD. Current treatment consists of injecting inhibitors of vascular endothelial growth factor (VEGF) into the vitreous cavity to interfere with proliferation of choroidal neovascularization and to reduce vascular permeability. It was […]
Dilsher Dhoot, AAO 2022: Sustained-release axitinib hydrogel implant in wet AMD, phase 1 results
A sustained-release axitinib hydrogel implant poses advantages for the treatment of wet age-related macular degeneration (wet AMD). In this touchOPHTHALMOLOGY interview, we speak with Dr Dilsher Dhoot (California Retina Consultants, Santa Barbara, CA, USA) to discuss the phase 1 study of the axitinib hydrogel implant, its findings and the next steps for its development. The […]
Journal articles and more to your inbox
Get the latest clinical insights from touchOPHTHALMOLOGYSign me up!